% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Foerster:277741,
      author       = {A. K. Foerster and E. M. Lauer and F. Scherer$^*$},
      title        = {{C}linical applications of circulating tumor {DNA} in
                      central nervous system lymphoma.},
      journal      = {Seminars in hematology},
      volume       = {60},
      number       = {3},
      issn         = {0037-1963},
      address      = {Philadelphia, Pa.},
      publisher    = {Saunders},
      reportid     = {DKFZ-2023-01458},
      pages        = {150-156},
      year         = {2023},
      note         = {2023 Jul;60(3):150-156},
      abstract     = {Detection and characterization of circulating tumor DNA
                      (ctDNA) in body fluids have the potential to revolutionize
                      management of patients with lymphoma. Minimal access to
                      malignant DNA through a simple blood draw or lumbar puncture
                      is particularly appealing for CNS lymphomas (CNSL), which
                      cannot be easily or repeatedly sampled without invasive
                      surgeries. Profiling of ctDNA provides a real-time snapshot
                      of the genetic composition in patients with CNSL and enables
                      ultrasensitive quantification of lymphoma burden at any
                      given time point during the course of the disease. Here, we
                      broadly review technical challenges of ctDNA identification
                      in CNSL, recent advances of innovative liquid biopsy
                      technologies, potential clinical applications of ctDNA and
                      how it may improve CNSL risk stratification, outcome
                      prediction, and monitoring of measurable residual disease.
                      Finally, we discuss clinical trials and scenarios in which
                      ctDNA could be implemented to guide risk-adapted and
                      personalized treatment decisions.},
      keywords     = {Central nervous system lymphoma (Other) / Circulating tumor
                      DNA (Other) / Minimal-invasive diagnosis of CNS lymphoma
                      (Other) / Ultrasensitive MRD monitoring (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37442670},
      doi          = {10.1053/j.seminhematol.2023.06.007},
      url          = {https://inrepo02.dkfz.de/record/277741},
}